NMTC (NeuroOne Medical Technologies) Institutional Ownership: 25.82% (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NMTC NeuroOne Medical Technologies Corp NMTC
21 GF Score
Price $1.96
! 4 Warning Signs
View Full Analysis

What is NeuroOne Medical Technologies Institutional Ownership?

NeuroOne Medical Technologies NMTC +2.70% 21 Institutional Ownership is 25.82% as of Jul. 25, 2026. GuruFocus rates NMTC with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NeuroOne Medical Technologies's institutional ownership is 25.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NeuroOne Medical Technologies's Insider Ownership is 17.51%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NeuroOne Medical Technologies's Float Percentage Of Total Shares Outstanding is 96.76%.

NeuroOne Medical Technologies Institutional Ownership Historical Data

* Premium members only.

The historical data trend for NeuroOne Medical Technologies's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroOne Medical Technologies Institutional Ownership Chart

NeuroOne Medical Technologies Historical Data

The historical data trend for NeuroOne Medical Technologies can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 4.98 4.98 4.98 4.48 4.52 4.53 4.55 4.53 5.78 6.08
NMTC
21GF Score
NeuroOne Medical Technologies Corp NMTC
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroOne Medical Technologies Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 25.82% mean?
NeuroOne Medical Technologies (NMTC) has a Institutional Ownership of 25.82% as of Jul. 25, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on NeuroOne Medical Technologies and its competitors.
Is NeuroOne Medical Technologies' Institutional Ownership too high?
NeuroOne Medical Technologies' current Institutional Ownership is 25.82%. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' Institutional Ownership compare to RDGL and TANAF?
NeuroOne Medical Technologies' Institutional Ownership of 25.82% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Devices & Instruments company?
A good Institutional Ownership depends on the Medical Devices & Instruments industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on NeuroOne Medical Technologies and its competitors. NeuroOne Medical Technologies's current Institutional Ownership is 25.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current Institutional Ownership of 25.82%. The current Institutional Ownership is 25.82%. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Institutional Ownership is 25.82% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroOne Medical Technologies Business Description

Address 7599 Anagram Drive, Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score

Get the complete analysis for NMTC

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.96
Price